HLX-3901

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameHLX-3901
Drug Alias NameHLX-3901
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Tetraspecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Delta-like protein 3Anti-CD3Anti-CD28
TargetsDelta-like protein 3T cell surface glycoprotein CD3T-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisSmall Cell Lung Carcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Fuhong Ruilin Biotechnology Co LtdShanghai Henlius Biologics Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisSmall Cell Lung Carcinoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A